12/18
08:03 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $4.00 price target on the stock.
High
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $4.00 price target on the stock.
12/18
07:00 am
espr
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
High
Report
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
12/17
08:54 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
12/13
12:42 pm
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
12/13
06:00 am
espr
Esperion Announces $210 Million Convertible Debt Financing
High
Report
Esperion Announces $210 Million Convertible Debt Financing
12/12
12:37 pm
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
12/12
08:17 am
espr
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel [Yahoo! Finance]
Low
Report
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel [Yahoo! Finance]
12/12
08:00 am
espr
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Medium
Report
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
12/3
09:01 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
12/2
08:00 am
espr
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
High
Report
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
11/27
08:05 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/26
08:06 am
espr
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia [Yahoo! Finance]
Low
Report
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia [Yahoo! Finance]
11/26
08:00 am
espr
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Low
Report
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
11/21
08:00 am
espr
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
11/19
08:20 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
High
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/18
10:40 am
espr
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]
Low
Report
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]
11/18
10:30 am
espr
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Low
Report
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
11/15
03:07 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/8
04:15 pm
espr
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/8
08:46 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/8
02:21 am
espr
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
11/7
12:35 pm
espr
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Low
Report
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
11/7
08:38 am
espr
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
06:00 am
espr
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Medium
Report
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
11/7
02:04 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.